NEONOD 2: Rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy.
Axillary lymph node dissection
Clinically positive axilla
Infiltrating breast cancer
Neoadjuvant chemotherapy
Outcome
Sentinel lymph node biopsy
Journal
Contemporary clinical trials communications
ISSN: 2451-8654
Titre abrégé: Contemp Clin Trials Commun
Pays: Netherlands
ID NLM: 101671157
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
11
07
2019
revised:
06
11
2019
accepted:
17
11
2019
entrez:
25
12
2019
pubmed:
25
12
2019
medline:
25
12
2019
Statut:
epublish
Résumé
Sentinel lymph node biopsy alone, without complete axillary lymph node dissection, is the standard treatment of the axilla nodal chain in early-stage breast cancer patients presenting a negative sentinel lymph node. The updated results of the IBCSG 23-01 randomized trial recently provided evidence that this approach could be extended to early-stage breast cancer patients presenting only micrometastasis in the sentinel lymph node. On the other hand, patients with large operable or locally advanced breast cancer and clinically positive lymph nodes currently receive neoadjuvant chemotherapy and sentinel lymph node biopsy, which is then followed by complete axillary node dissection if the sentinel lymph node till contains tumor residue, regardless of the extent of nodal disease. Assuming that patients presenting only a micrometastatic sentinel lymph node after neoadjuvant chemotherapy are clinically equivalent to the IBCSG 23-01 early-breast cancer patients with only micrometastatic sentinel node, then complete axillary dissection would be unneeded also in these subset of patients in the neoadjuvant setting. The multicenter uncontrolled non-inferiority trial NEONOD 2 we here present was designed to assess this hypothesis, i.e. whether or not omission of complete axillary nodal clearance worsens prognosis in patients with sentinel node resulting only micrometastatic after neoadjuvant chemotherapy.
Identifiants
pubmed: 31872159
doi: 10.1016/j.conctc.2019.100496
pii: S2451-8654(19)30258-3
pii: 100496
pmc: PMC6909193
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100496Informations de copyright
© 2019 The Author(s).
Déclaration de conflit d'intérêts
None.
Références
Ann Oncol. 2009 Jun;20(6):1001-7
pubmed: 19174453
J Clin Oncol. 2015 Jan 20;33(3):258-64
pubmed: 25452445
Nat Rev Clin Oncol. 2015 Jun;12(6):335-43
pubmed: 25850554
J Surg Oncol. 2010 Aug 1;102(2):111-8
pubmed: 20648579
Eur J Surg Oncol. 2011 Aug;37(8):688-94
pubmed: 21696914
Ann Surg Oncol. 2016 Oct;23(11):3467-3474
pubmed: 27160528
J Clin Oncol. 1997 Jul;15(7):2483-93
pubmed: 9215816
J Clin Oncol. 2005 Dec 20;23(36):9304-11
pubmed: 16361629
J Natl Cancer Inst. 2006 May 3;98(9):599-609
pubmed: 16670385
Lancet Oncol. 2018 Oct;19(10):1385-1393
pubmed: 30196031
Ann Surg Oncol. 2016 Aug;23(8):2494-500
pubmed: 26975739
Lancet Oncol. 2013 Jun;14(7):609-18
pubmed: 23683750
Breast Cancer Res Treat. 2017 May;163(1):159-166
pubmed: 28213782
N Engl J Med. 2003 Aug 7;349(6):546-53
pubmed: 12904519
Ann Surg. 2008 Feb;247(2):207-13
pubmed: 18216523
Clin Cancer Res. 2007 Jan 1;13(1):228-33
pubmed: 17200359
Lancet Oncol. 2013 Apr;14(4):297-305
pubmed: 23491275
N Engl J Med. 1998 Oct 1;339(14):941-6
pubmed: 9753708
Breast. 2016 Dec;30:197-200
pubmed: 27406897
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
JAMA. 2013 Oct 9;310(14):1455-61
pubmed: 24101169
J Natl Cancer Inst. 1990 Oct 3;82(19):1539-45
pubmed: 2402015